These results suggest that CYP1B1 and CYP2C9 SNPs alone or in combination with other clinical and genetic markers might help to improve the ability to predict the appearance of bone erosions in seropositive patients (~70% of RA patients). This evidence concerns the gene CYP2C9 and rheumatoid arthritis.